DDInter1291 DDInter899
Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is [amlodipine]. Nifedipine was granted FDA approval on 31 December 1981.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Nifedipine {u} (Compound) resembles {v} (Compound) Isradipine
Nifedipine {u} (Compound) resembles {v} (Compound) Nicardipine
Nifedipine {u} (Compound) treats {v} (Disease) hypertension
Nifedipine {u} (Compound) binds {v} (Gene) CALM1
Nifedipine {u} (Compound) upregulates {v} (Gene) MTHFD2
Nifedipine {u} (Compound) palliates {v} (Disease) systemic scleroderma
Nifedipine {u} (Compound) is included by {v} (Pharmacologic Class) Dihydropyridines
Nifedipine {u} (Compound) downregulates {v} (Gene) FOXO4
Nifedipine {u} (Compound) causes {v} (Side Effect) Sleep disorder
Nifedipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Nifedipine (Compound) resembles Isradipine (Compound)
Nifedipine (Compound) resembles Nicardipine (Compound)
Nifedipine (Compound) treats hypertension (Disease)
Nifedipine (Compound) binds CALM1 (Gene)
Nifedipine (Compound) upregulates MTHFD2 (Gene)
Nifedipine (Compound) palliates systemic scleroderma (Disease)
Nifedipine (Compound) is included by Dihydropyridines (Pharmacologic Class)
Nifedipine (Compound) downregulates FOXO4 (Gene)
Nifedipine (Compound) causes Sleep disorder (Side Effect)
Nifedipine may cause a minor interaction that can limit clinical effects when taken with Darolutamide